Sanofi sues Novo Nordisk over diabetes drugs in the U.S.
Reuters
Published Dec 28, 2016 00:55
Sanofi sues Novo Nordisk over diabetes drugs in the U.S.
By Matthias Blamont and Brendan Pierson
(Reuters) - France's Sanofi (PA:SASY) has filed a lawsuit in the United States accusing Novo Nordisk (CO:NOVOb) of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
The complaint, filed by Sanofi US in U.S. District Court for the District of New Jersey on Dec. 23, seeks an order forcing Novo Nordisk to pay unspecified money damages and withdraw marketing materials for its drug Tresiba.
The marketing materials urge doctors and patients to switch from Sanofi's drugs Lantus and Toujeo, used to treat diabetes, to Tresiba, according to Sanofi, because the Sanofi drugs will be "blocked" by U.S. pharmacy benefit manager CVS Caremark (N:CVS) in January.
Sanofi said CVS is replacing the drugs with Eli Lilly's (N:LLY) similar, cheaper drug Basaglar on its so-called standard formulary, a list of drugs that health insurance plans cover.
Many health plans do not use CVS' standard formulary, and some that do will likely continue to cover the Sanofi drugs, though patients will have to pay more for them, Sanofi said. Sanofi also said it offers assistance to individuals to buy the drugs if their insurance does not cover them.
Novo Nordisk had no comment.
"(W)e believe Novo's statements concerning CVS Caremark's formulary decision on Lantus and Toujeo coverage contain false and misleading claims about the continued availability of Lantus and Toujeo," said a Sanofi spokeswoman in an emailed statement.
Lantus and Toujeo are two of the diabetes treatments that Sanofi sells in the United States, the world's largest health market.
Pressure has been rising on its U.S. diabetes business in recent months as CVS and insurer UnitedHealth Group Inc (N:UNH) announced plans to replace Lantus and Toujeo with Basaglar.
Sanofi posted better-than-expected quarterly earnings in October and lifted its profit outlook for the year. But the drugmaker stuck to its forecast that currency-adjusted sales at its embattled diabetes business would shrink by 4 percent to 8 percent per year on average from 2015 to 2018.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.